TY - JOUR
T1 - Update on biomarkers in neuromyelitis optica
AU - GJCFICC&BR
AU - Melamed, Esther
AU - Levy, Michael
AU - Waters, Patrick J.
AU - Sato, Douglas Kazutoshi
AU - Bennett, Jeffrey L.
AU - John, Gareth R.
AU - Hooper, Douglas C.
AU - Saiz, Albert
AU - Bar-Or, Amit
AU - Kim, Ho Jin
AU - Pandit, Lakha
AU - Leite, Maria Isabel
AU - Asgari, Nasrin
AU - Kissani, Najib
AU - Hintzen, Rogier
AU - Marignier, Romain
AU - Jarius, Sven
AU - Marcelletti, John
AU - Smith, Terry J.
AU - Yeaman, Michael R.
AU - Han, May H.
AU - Aktas, Orhan
AU - Apiwattanakul, Metha
AU - Banwell, Brenda
AU - Bichuetti, Denis Bernardi
AU - Broadley, Simon A.
AU - Cabre, Philippe
AU - Chitnis, Tanuja
AU - de Sèze, Jérôme
AU - Fujihara, Kazuo
AU - Greenberg, Benjamin M.
AU - Hellwig, Kerstin
AU - Iorio, Raffaele
AU - Klawiter, Eric C.
AU - Kleiter, Ingo
AU - Lana-Peixoto, Marco Aurélio
AU - Nakashima, Hideyuki
AU - O'connor, K.
AU - Palace, Jackie
AU - Paul, Friedman A.
AU - Prayoonwiwat, Naraporn
AU - Ruprecht, Klemens
AU - Stuve, Olaf
AU - Tedder, Thomas F.
AU - Tenembaum, Silvia N.
AU - Garrahan, Juan P.
AU - Aires, Buenos
AU - van Herle, Katja
AU - van Pelt, Danielle
AU - Villoslada, Pablo
N1 - Publisher Copyright:
© 2015 American Academy of Neurology.
PY - 2015
Y1 - 2015
N2 - Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.
AB - Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.
UR - http://www.scopus.com/inward/record.url?scp=84969320801&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969320801&partnerID=8YFLogxK
U2 - 10.1212/NXI.0000000000000134
DO - 10.1212/NXI.0000000000000134
M3 - Review article
C2 - 26236760
AN - SCOPUS:84969320801
SN - 2332-7812
VL - 2
JO - Neurology: Neuroimmunology and NeuroInflammation
JF - Neurology: Neuroimmunology and NeuroInflammation
IS - 4
M1 - e134
ER -